About
There are major unaddressed issues in Alzheimer’s Disease clinical practice such as:
- Identifying accessible fluid biomarker to determine time for reaching amyloid negativity to know when to stop treatment
- Understanding impact of disease state on functional outcome
- Understanding impact of baseline tau load on functional outcome
We use a combination of a mechanistic Quantitative Systems Pharmacology (QSP) model of amyloid aggregation with a computational neuroscience model, calibrated on functional scales with symptomatic treatments to understand these unaddressed clinical issues.